Founder, CEO & CIO, Ally Bridge Group
As Founder, CEO and CIO, Mr. Yu has established Ally Bridge Group (ABG) as a truly global life science-focused investment group with teams/offices in Hong Kong, New York and Europe and a portfolio of world-leading life science technologies with approximately US$2.5 billion in assets under management (mostly in life science). ABG initiated, led and completed the US$3.3 billion take-private of Wuxi Pharmatech from NYSE, which has proven highly successful. Under Mr. Yu’s leadership, since 2015 ABG launched two successful life science sector-dedicated hedge funds – Ally Bridge LB Healthcare Fund in Hong Kong and Ally Bridge MedAlpha Fund in New York.
Previously, Mr. Yu was Managing Director and Head of China Investments at Och-Ziff Capital Management (OZ), a leading global hedge fund, where he made some of OZ’s largest and highly successful investments. Prior to Och-Ziff, Mr. Yu was a Managing Director at Goldman Sachs in Hong Kong, where he headed several business units and led some of the most important restructuring, IPOs and M&A transactions in China. Before Goldman Sachs, Mr. Yu worked at Moody’s in New York, and then at Credit Suisse in London and Hong Kong where he was dedicated to risk management.